SEC Filing Summary: Aadi Bioscience, Inc. (AADI) - Form 10-Q
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for cancers with alterations in the mTOR pathway. Its lead product, FYARRO (nab-sirolimus), is approved by the FDA for the treatment of advanced malignant perivascular epithelioid cell tumor (PEComa). The company is currently conducting a comprehensive strategic review to maximize shareholder value following the halting of its registration-intended PRECISION1 clinical trial.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $7,212 | $5,959 | $18,744 | $18,028 |
| Net Loss | $(12,546) | $(16,302) | $(45,418) | $(49,496) |
| Loss Per Share (Basic/Diluted) | $(0.46) | $(0.60) | $(1.68) | $(1.84) |
| Operating Expenses | $20,625 | $23,808 | $67,253 | $72,247 |
| Cash & Short-Term Investments | $62,619 | $108,845 | $62,619 | $108,845 |
| Accumulated Deficit | $(314,381) | $(252,694) | $(314,381) | $(252,694) |
Note: Cash and short-term investments are derived from the balance sheet ($30,537 cash + $32,082 short-term investments).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 21% in Q3 2024 compared to Q3 2023, driven by strong demand for FYARRO. Year-to-date revenue increased 4%.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased significantly ($7.2M in Q3 2024 vs. $11.2M in Q3 2023) due to workforce reductions and lower commercial/marketing spend. Research and development (R&D) expenses also declined ($10.0M vs. $11.9M).
- Restructuring Charges: The company recorded a one-time restructuring charge of $2.6 million in Q3 2024 related to a 32% workforce reduction and the termination of the PRECISION1 trial. No such charges were recorded in the prior year.
- Liquidity Position: Cash and short-term investments decreased from $108.8 million at December 31, 2023, to $62.6 million at September 30, 2024, primarily due to operating cash outflows and a $5.8 million payment to Bristol-Myers Squibb (BMS) to settle a license obligation.
Guidance, Outlook, and Management Commentary
- Strategic Review: Management announced a comprehensive strategic review in August 2024 to maximize shareholder value. Options under consideration include a merger, sale, wind-down, or liquidation.
- Clinical Trial Updates: The company halted the PRECISION1 trial (TSC1/TSC2 alterations) based on interim efficacy data. Enrollment in Phase 2 trials for endometrial cancer (EEC) and neuroendocrine tumors (NETs) has been paused, though dosing of enrolled patients continues.
- Liquidity Runway: Management believes current cash resources ($62.6 million) are sufficient to fund operations into the second half of 2026.
- Legal Resolution: The company won a final arbitration award against EOC Pharma (Hong Kong) Limited in September 2024, finding Aadi not liable for damages regarding the terminated license agreement.
- Risks: Key risks include the uncertainty of the strategic review outcome, dependence on a single product (FYARRO), reliance on a single manufacturer (Fresenius Kabi) whose agreement expired September 30, 2024, and the need for additional capital if profitability is not achieved.
Investor Verification Checklist
- Strategic Transaction Status: Verify the progress and potential outcomes of the ongoing strategic review (merger, sale, or liquidation).
- Manufacturing Supply Chain: Confirm the status of the new supply agreement with Fresenius Kabi, as the previous agreement expired on September 30, 2024.
- Cash Burn Rate: Monitor quarterly cash usage to validate the management's projection of funding operations through the second half of 2026.
- Regulatory Milestones: Track the release of final data from the PRECISION1 trial (expected 2025) and initial efficacy signals from the paused EEC and NET trials (expected Q4 2024).
- Restructuring Completion: Verify the completion of the $2.6 million restructuring payments and the resulting impact on future operating expenses.